Skip to content

Proof-of-Concept Study Assessing VNS Paired With Tones for Tinnitus

A Proof-of-Concept Pilot Study Assessing Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01253616
Enrollment
10
Registered
2010-12-03
Start date
2010-12-31
Completion date
2012-06-30
Last updated
2017-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Tinnitus

Brief summary

This is a proof-of-concept study designed to provide feasibility information on the clinical use of vagus nerve stimulation (VNS) paired with tones for the treatment of severe tinnitus. The study is expected to give preliminary efficacy and safety information.

Interventions

Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).

Sponsors

MicroTransponder Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Key Inclusion Criteria: * 18 to 65 years of age * Diagnosed with subjective tinnitus due to hearing loss with at least some tonal quality of the tinnitus. * Diagnosis of tinnitus for at least one year * Tinnitus severity of 18 or greater on TRQ cross checked with TQ severity of Grade 3 or worse Key

Exclusion criteria

* Acute or intermittent tinnitus * Severe hearing loss * History of significant ear disease such as Meniere's disease, ear tumors, or evidence of active middle ear disease. * Any other implanted device

Design outcomes

Primary

MeasureTime frame
Audiometric measurementsweekly through one month

Secondary

MeasureTime frame
tinnitus questionairesweekly through one month
adverse eventsas they occur

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026